跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 16 条关于
“GenFleet”
全部
16
临床试验
0
药物
0
机构
3
资讯
13
前天
GenFleet's Oral KRAS G12D Inhibitor GFH375 Posts Strong Phase II Results in Pretreated NSCLC, Paving Way for First Global Phase III
上个月
GenFleet's Oral KRAS G12D Inhibitor GFH375 Enters Registrational Phase III Trial in NSCLC, First of Its Kind Globally
去年
Chinese Firms Expand Solo Global Phase III Activity Including US Sites
去年
RIPK1 Inhibitor Pipeline Shows Promise Despite Sanofi Setback in Multiple Sclerosis
11个月前
HengRui Advances KRAS G12D Inhibitor HRS-4642 to Phase 3 Trial in Pancreatic Cancer
去年
Cancer Cachexia Pipeline Shows Promise with 20+ Therapies in Development Across Multiple Companies
去年
Advancements and Challenges in Clinical Trials: A 2024 Overview
去年
Verastem Oncology Refinances Debt and Advances Avutometinib/Defactinib Combination
去年
Verastem Oncology Completes NDA Submission for Avutometinib/Defactinib in Recurrent KRAS Mutant LGSOC
2年前
Verastem Oncology's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant LGSOC
第 1 页,共 2 页
上一页
下一页